AACR roundup: Check­point cock­tails score ear­ly suc­cess­es as Roche's triple shows high re­sponse rate in front­line triple neg­a­tive breast can­cer

Roche to­day spelled out its best ear­ly-stage case for a new triple ther­a­py com­bo to tack­le triple neg­a­tive breast can­cer — a par­tic­u­lar­ly lethal va­ri­ety of can­cer that has proven tough to treat.

Read on for more: Lit­tle TG Ther­a­peu­tics looks for ap­plause on lat­est um­bral­is­ib da­ta; Add-on from Chi-Med, As­traZeneca helps Tagris­so-re­sis­tant lung can­cer pa­tients; Astel­las spells out pos­i­tive Xospa­ta PhI­II da­ta in AML pa­tients; Pre­clin­i­cal neoanti­gen study finds 4 promis­ing tar­gets for spurring an im­mune re­sponse

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER